ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Unravelling the Mysteries of ME/CFS and Fibromyalgia: Meet the Man Behind the Book

16 Tips from 16 Years Sick

How Myofascial Release Got Me Back On My Feet Again

NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research

When Things Go Wrong, We Learn!

Cort Johnson Interviews ME/CFS Victor Martha Kilcoyne

Caregivers Draw Support By Mapping Their Relationships

Pediatric Chronic Pain: Prevalence, economic impact, and its relevance to the current opioid epidemi...

Ten Years with ME. This One May Take the Cake

Three NIH Funded ME/CFS Research Centers….and (What Else?) a Controversy

 
Print Page
Email Article

Cymbalta vs. Lyrica: Medical Costs and Medication Compliance Among Fibromyalgia Patients

  [ 3 votes ]   [ Discuss This Article ]
www.ProHealth.com • March 26, 2013


Editor's Note: This study compares both total medical costs and medication compliance among fibromyalgia patients who began taking either duloxetine (Cymbalta) or pregabalin (Lyrica) during the year 2008.  At that time, milnacipran (Savella) had not yet been approved for treating FM. 

Direct Medical Costs and Medication Compliance among Fibromyalgia Patients: Duloxetine Initiators vs. Pregabalin Initiators.
– Source: Pain Practice, March 14, 2013

By P. Sun, et al.

Abstract:

OBJECTIVES: To assess and compare direct medical costs and medication compliance between patients with fibromyalgia who initiated duloxetine and patients with fibromyalgia who initiated pregabalin in 2008.

METHODS:
A retrospective cohort study design was used based on a large US national commercial claims database (2006 to 2009). Patients with fibromyalgia aged 18 to 64 who initiated duloxetine or pregabalin in 2008 and who had continuous health insurance 1 year preceding and 1 year following the initiation were selected into duloxetine cohort or pregabalin cohort based on their initiated agent.

Medication compliance was measured by total supply days, medication possession ratio (MPR), and proportion of patients with MPR  ?  0.8. Direct medical costs were measured by annual costs per patient and compared between the cohorts in the year following the initiation. Propensity score stratification and bootstrapping methods were used to adjust for distribution bias, as well as cross-cohort differences in demographic, clinical and economic characteristics, and medication history prior to the initiation.

RESULTS: Both the duloxetine (n  =  3,033) and pregabalin (n  =  4,838) cohorts had a mean initiation age around 49  years, 89% were women.

During the postindex year, compared to the pregabalin cohort, the duloxetine cohort had

  • higher totally annual supply days (273.5 vs. 176.6, P  <  0.05),

  • higher MPR (0.7 vs. 0.5, P  <  0.05),

  • and more patients with MPR  ?  0.8 (45.1% vs. 29.4%, P  <  0.05).

Further, relative to pregabalin cohort, duloxetine cohort had

  • lower inpatient costs ($2,994.9 vs. $4,949.6, P  <  0.05),

  • lower outpatient costs ($8,259.6 vs. $10,312.2, P  <  0.05),

  • similar medication costs ($5,214.6 vs. $5,290.8, P  >  0.05),

  • and lower total medical costs ($16,469.1 vs. $20,552.6, P  <  0.05) in the postinitiation year.

CONCLUSIONS: In a real-world setting, patients with fibromyalgia who initiated duloxetine in 2008 had better medication compliance and consumed less inpatient, outpatient, and total medical costs than those who initiated pregabalin.


Source: Pain Practice, March 14, 2013. By P. Sun, X. Peng, S. Sun, D. Novick, D.E. Faries, J.S. Andrews, M.M. Wohlreich, and A. Wu. Kailo Research Group, Indianapolis, IN, U.S.A.





Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg MitoQ® Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Improve Cardiovascular and Metabolic Health with Omega-7 Improve Cardiovascular and Metabolic Health with Omega-7
Secret Nutrient for Radiant Skin Secret Nutrient for Radiant Skin
Inflammation Disrupts Memory - What Can You Do to Protect Your Brain? Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?
Bone Broth Benefits for Digestion, Arthritis and Cellulite Bone Broth Benefits for Digestion, Arthritis and Cellulite
The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map